Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety

Journal of Clinical Psychopharmacology

Volumn 33, Issue 1, 2013, Pages 95-98

  Vitali, Mario ^a,b,c   Tedeschini, Enrico ^d   Mistretta, Martino ^e   Fehling, Kiki ^c   Aceti, Franca ^e   Ceccanti, Mauro ^a   Fava, Maurizio ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF ROME   (Italy)

Author keywords

adjunctive pregabalin; antidepressants; MDD; partial responders; residual anxiety

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; CLINICAL ARTICLE; DEMENTIA; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; MAJOR DEPRESSION; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SOMATIZATION; SOMNOLENCE; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC AGENTS; AGED; ANTI-ANXIETY AGENTS; ANXIETY; DEPRESSIVE DISORDER, MAJOR; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873091228     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31827b9351     Document Type: Article

References (29)

1. Mykletun A, Bjerkeset O, Overland S, et al. Levels of anxiety and depression as predictors of mortality: the HUNT study. Br J Psychiatry. 2009;195:118-125.
2. Cuijpers P, Schoevers RA. Increased mortality in depressive disorders: a review. Curr Psychiatry Rep. 2004;6:430-437.
3. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000;57:375-380.
4. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR&z.ast;D) study. Psychiatr Clin North Am. 2003;26:457-494.
5. Fava M, Davidson K, Alpert JE, et al. Hostility changes following antidepressant treatment: relationship to stress and negative thinking. J Psychiatr Res. 1996;30:459-467.
6. Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol. 2006;20:29-34.
7. Fava M, Rosenbaum JF. Anger attacks in patients with depression. J Clin Psychiatry. 1999;60:21-24.
8. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord. 1997;45:5-17.
9. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62:4-11.
10. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR&z.ast;D report. Am J Psychiatry. 2008;165:342-351.
11. Iovieno N, van Niewenhuizen A, Clain A, et al. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety. 2011;28:137-144.
12. Taylor DJ, Walters HM, Vittengl SK, et al. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J Affect Disord. 2010;123:181-187.
13. Dombrovski AY, Mulsant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord. 2007;103:77-82.
14. McIntyre RS, Konarski JZ, Soczynska JK, et al. Residual anxiety symptoms in depressed primary care patients. J Psychiatr Pract. 2007; 13:125-128.
15. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86: 99-104.
16. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792-805.
17. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419-431.
18. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52: 1264-1273.
19. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502-514.
20. Kinsora JJ Jr, Serpa KA, Snyder BJ, et al. Anxiolytic-like effects of pregabalin. Abstracts of the Society for Neuroscience. 1999;25:1319.
21. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240-249.
22. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003; 160:533-540.
23. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24:141-149.
24. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022-1030.
25. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67:771-782.
26. Stein DJ, Baldwin DS, Baldinetti F, et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008;18: 422-430.
27. Showraki M. Pregabalin in the treatment of depression. J Psychopharmacol. 2007;21:883-884.
28. Pae CU. Pregabalin augmentation to antidepressants in patients with major depressive disorder. [Letter to the editor.] Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:577-578.
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.